Ligand validation:2OIP

CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID

CB3 is a Ligand Of Interest in 2OIP designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2OIP_CB3_B_608	43%	3%	0.208	0.934	3.17	2.93	25	18	1	0	100%	1
2OIP_CB3_C_612	30%	4%	0.228	0.893	2.44	3.23	20	23	2	1	100%	1
2OIP_CB3_A_604	16%	6%	0.3	0.875	2.21	2.85	15	23	0	0	100%	1
2OIP_CB3_D_616	8%	10%	0.342	0.825	2.09	2.2	17	13	0	0	100%	1
2OIP_CB3_E_620	1%	21%	0.529	0.646	1.24	2.07	2	7	11	1	100%	1
3DL5_CB3_B_608	40%	19%	0.205	0.917	1.29	2.12	2	9	2	0	100%	1
3DL6_CB3_C_612	22%	21%	0.29	0.906	1.29	2.01	3	9	9	0	100%	1
1QZF_CB3_E_620	14%	12%	0.28	0.835	2.05	2	11	5	2	1	100%	1
3HJ3_CB3_A_604	3%	12%	0.375	0.705	2.11	2.01	12	6	9	1	100%	1
4GEV_CB3_A_702	96%	26%	0.058	0.966	1.18	1.82	3	8	0	0	100%	1
6NNR_CB3_B_302	93%	19%	0.076	0.97	1.19	2.25	3	8	0	0	100%	1
2AAZ_CB3_E_2551	92%	5%	0.081	0.973	2.5	2.75	16	15	0	0	100%	0.25
2FTO_CB3_X_266	82%	17%	0.087	0.943	1.58	2	6	6	1	0	100%	1
4EIL_CB3_G_702	76%	9%	0.105	0.941	1.96	2.43	8	13	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.